Literature DB >> 2160914

Efficacy of prolonged therapy with stibogluconate in post kala-azar dermal leishmaniasis.

C P Thakur1, K Kumar.   

Abstract

Fifty three (30 male and 23 female), previously untreated, patients with post kala-azar dermal leishmaniasis (PKDL) were treated with sodium stibogluconate, at the dose of 20 mg/kg/bw/d/im/(with a maximum of 8.5 ml) for 120 days (or more, if necessary). All the patients were followed up for 12 months. The patients were assessed after 40 days and thereafter at an interval of 20 days. The mean age of onset was 24 yr, maximum number of patients developed the disease within 3 yr of apparent cure of kala-azar. Maximum number of patients sought treatment within 5 yr of the onset of PKDL. The disease affected the face (98%), trunk (83%), upper limb (72%), lower limb (40%), genetalia (6%), and mucus membrane of the tongue 40%. The lesions observed were nodules (19%), papules (30%), and hypopigmented (45%) and reddish macules (7%). The parasites could be demonstrated in the nodules (100%), papules (69%) and macules (59%). The response to treatment started in 72 per cent of patients in the first 20 days and in 40 days in all patients. All the nodules and papules disappeared in 120 days, and the macules within 200 days. The side effects of treatment noted were changes in S T and T in electrocardiogram (7%), arthralgia (11%), allergic rash (7%), swelling at the site of injection (5%), neuralgia (4%) and metalic taste (6%). The S T and T changes reverted to normal when the drug was discontinued for 20 days. Arthralgia improved with indomethacin. The higher dosages and longer course of treatment were well tolerated and resulted in a cure in all patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2160914

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  7 in total

Review 1.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

2.  New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas.

Authors:  Kathryn M Dupnik; Eliana L Nascimento; Joao F Rodrigues-Neto; Tatjana Keesen; Maria Zélia Fernandes; Iraci Duarte; Selma M B Jeronimo
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

3.  Economic consequences of post-kala-azar dermal leishmaniasis in a rural Bangladeshi community.

Authors:  Masayo Ozaki; Shamim Islam; Kazi Mizanur Rahman; Anisur Rahman; Stephen P Luby; Caryn Bern
Journal:  Am J Trop Med Hyg       Date:  2011-09       Impact factor: 2.345

Review 4.  Of cattle, sand flies and men: a systematic review of risk factor analyses for South Asian visceral leishmaniasis and implications for elimination.

Authors:  Caryn Bern; Orin Courtenay; Jorge Alvar
Journal:  PLoS Negl Trop Dis       Date:  2010-02-09

5.  Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis.

Authors:  Shyam Sundar; Anup Singh; Jaya Chakravarty; Madhukar Rai
Journal:  ScientificWorldJournal       Date:  2015-01-01

6.  Efficacy and Safety of Paromomycin in Treatment of Post-Kala-Azar Dermal Leishmaniasis.

Authors:  Shyam Sundar; Anup Singh; Anurag Tiwari; Saurabh Shukla; Jaya Chakravarty; Madhukar Rai
Journal:  ISRN Parasitol       Date:  2014-03-06

7.  Treatment-based strategy for the management of post-kala-azar dermal leishmaniasis patients in the Sudan.

Authors:  A M Musa; E A G Khalil; B M Younis; M E E Elfaki; M Y Elamin; A O A Adam; H A A Mohamed; M M M Dafalla; A A Abuzaid; A M El-Hassan
Journal:  J Trop Med       Date:  2013-04-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.